A Study of NT-112 and AZD0240 in People With Solid Tumor Cancer

Full Title

An Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T cells Recognizing KRAS Mutations in Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors

Purpose

 To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Adam Schoenfeld’s office at 646-608-4042.

Protocol
26-131
Phase
Phase I (phase 1)
Investigator
Adam J. Schoenfeld
Co-Investigators
Kenneth H. Yu
Diseases
Colorectal Cancer
Gynecologic Cancer › Uterine (Endometrial) Cancer
Hepatobiliary › Pancreatic Cancer
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06218914
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description